About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Philadelphia | 448 Studies

Clinical Trials LymphomaPhiladelphia

Lymphoma Clinical Trials in Philadelphia

Find 448 clinical trials for lymphoma near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 141-160 of 448 trials

CompletedBortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyThis phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or…NCT00381940·Philadelphia, Pennsylvania CompletedCollecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaThis research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma.NCT00897325·Birmingham, Alabama and 182 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

TerminatedSirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer cells from dividing so they stop growing or die.NCT00068302·Philadelphia, Pennsylvania

RecruitingCD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T…NCT06420089·New York, New York and 1 other

CompletedSafety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsThis Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R)…NCT05225584·Orange, California and 12 others

CompletedCombination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin LymphomaThis phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.NCT01026220·Birmingham, Alabama and 176 others

CompletedSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR…NCT03213678·Birmingham, Alabama and 126 others

CompletedA Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced CancerPD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors).NCT00141297·Detroit, Michigan and 3 others

CompletedA Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLThis is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; \[G\]), rituximab (R) and standard doses of CHOP…NCT03467373·Birmingham, Alabama and 21 others

Active not recruitingA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.NCT04245839·Santa Monica, California and 48 others

TerminatedStudy of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTargeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.NCT04305444·Phoenix, Arizona and 7 others

Active not recruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialThis phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to…NCT04320888·Birmingham, Alabama and 173 others

TerminatedRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.NCT00335140·Stanford, California and 67 others

CompletedDose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic LeukaemiaThe study is in two parts: a dose escalation then a safety dose expansion.NCT02746952·Boston, Massachusetts and 8 others

TerminatedA Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.NCT04035434·Los Angeles, California and 32 others

TerminatedRituximab in Treating Patients With Refractory or Relapsed Primary CNS LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00072449·Birmingham, Alabama and 8 others

CompletedPhase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsThe purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin…NCT03610724·Los Angeles, California and 25 others

RecruitingPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionThe use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.NCT06131801·Aurora, Colorado and 5 others

RecruitingSTimulation to Activate RespIrationMulti-center, randomized, controlled, open-label Phase 2 feasibility trial.NCT06832306·La Jolla, California and 6 others

CompletedCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaRATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.NCT00133991·Baltimore, Maryland and 1 other

PreviousPage 8 of 23Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia